期刊论文详细信息
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy
and the Alzheimer's Disease Neuroimaging Initiative1  Alan C. Evans2  Phil Hyu Lee3  Mincheol Park3  Byoung Seok Ye3  Seok Jong Chung3  Sung Woo Kang3  Han Soo Yoo3  Jin Ho Jung3  Seun Jeon3  Young‐gun Lee3  Kyoungwon Baik3  Seong Ho Jeong3  Young Ho Sohn3 
[1] ;Brain Research Institute Yonsei University College of Medicine Seoul Korea;Department of Neurology Inje University Busan Paik Hospital Busan Korea;
关键词: α‐synuclein;    Alzheimer's disease;    cerebrospinal fluid biomarkers;    Lewy body disease;    polygenic risk score;   
DOI  :  10.1002/dad2.12177
来源: DOAJ
【 摘 要 】

Abstract Introduction Lewy body–related pathology is commonly observed at autopsy in individuals with dementia, but in vivo biomarkers for α‐synucleinopathy are lacking. Methods Baseline cerebrospinal fluid (CSF) biomarkers, polygenic risk score (PRS) for Parkinson's disease (PRS‐PD) and Alzheimer's disease (PRS‐AD), longitudinal cognitive scores, and magnetic resonance imaging were measured in 217 participants from the Alzheimer's Disease Neuroimaging Initiative. Linear mixed models were used to find the relationship of CSF biomarkers and the PRS with cognition and cortical atrophy. Results Higher PRS‐PD and PRS‐AD were associated with lower CSF α‐synuclein and amyloid beta (Aβ), respectively. Lower CSF α‐synuclein and the interaction of CSF α‐synuclein and Aβ were associated with lower cognitive scores and global cortical atrophy most prominently in the occipital cortex. Discussion Lower CSF α‐synuclein could be a biomarker for α‐synucleinopathy, and the simultaneous evaluation of CSF biomarkers for AD and CSF α‐synuclein could reveal the independent and interactive effects on cognition and cortical atrophy.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:1次